Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sgn-alpv
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SGN-ALPV is a novel, investigational antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody targeting placental alkaline phosphatase (ALPP) and ALPP-like 2 (ALPPL2), conjugated via a protease-cleavable linker to the microtubule-disrupting agent monomethyl auristatin E (MMAE). The drug binds to ALPP or ALPPL2 on the surface of tumor cells, is internalized, and releases MMAE in the cytoplasm after lysosomal cleavage. MMAE then binds tubulin, inhibiting microtubule polymerization, leading to cell cycle arrest and apoptosis. Additional mechanisms include immunogenic cell death and bystander killing of neighboring cells. SGN-ALPV was developed for cancers with high expression of ALPP/ALPPL2 such as ovarian, endometrial, gastric, testicular germ cell tumors, non-small cell lung cancer (NSCLC), cervical cancer, and other advanced solid tumors[1][2][6].
- Other names
- anti-ALPP/ALPG ADC
02
Targets
ALPP (Alkaline phosphatase, placental type)ALPG (Alkaline phosphatase, placental-like 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on sgn-alpv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sgn-alpv.